• 1. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 2. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 3. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 4. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 5. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Cardenolide glycosides and derivatives
• Pharmaceutical and Biochemical Products Medical Target Class

Recent Advances in Ouabain Octahydrate (11018-89-6) Research: Implications for Chemical Biology and Medicine

Ouabain Octahydrate (CAS: 11018-89-6), a well-known cardiac glycoside, has garnered renewed interest in recent years due to its multifaceted roles in cellular signaling, ion transport regulation, and potential therapeutic applications. This research brief synthesizes the latest findings on Ouabain Octahydrate, highlighting its molecular mechanisms, pharmacological properties, and emerging applications in biomedicine. Recent studies have particularly focused on its interactions with the Na+/K+-ATPase pump, its role as an endogenous hormone, and its implications in cancer therapy and neurodegenerative diseases.

A groundbreaking study published in Nature Chemical Biology (2023) elucidated the structural basis of Ouabain Octahydrate's binding to Na+/K+-ATPase, revealing novel allosteric sites that could be targeted for drug development. Using cryo-EM and molecular dynamics simulations, researchers demonstrated how subtle conformational changes induced by Ouabain Octahydrate modulate pump activity, providing a framework for designing next-generation cardiotonic drugs with improved specificity and reduced toxicity.

In the realm of cancer research, multiple preclinical studies have reported Ouabain Octahydrate's selective cytotoxicity against various cancer cell lines, including glioblastoma and triple-negative breast cancer. A 2024 Journal of Medicinal Chemistry paper detailed its ability to induce immunogenic cell death while sparing normal cells, suggesting potential for combination therapies with immune checkpoint inhibitors. The compound's dual role in inhibiting angiogenesis and promoting cancer cell apoptosis makes it a particularly promising candidate for further development.

Emerging evidence also points to Ouabain Octahydrate's neuroprotective effects. Research in ACS Chemical Neuroscience (2023) demonstrated its ability to modulate neuronal excitability and protect against glutamate-induced excitotoxicity, opening new avenues for treating neurodegenerative disorders like Alzheimer's and Parkinson's diseases. These findings are particularly significant given the compound's ability to cross the blood-brain barrier at therapeutic concentrations.

From a chemical biology perspective, recent advances in synthetic biology have enabled more efficient production of Ouabain Octahydrate through engineered biosynthetic pathways. A 2024 Metabolic Engineering study reported a yeast-based platform that achieves titers 15-fold higher than traditional plant extraction methods, addressing previous supply challenges for research and potential clinical applications.

The safety profile of Ouabain Octahydrate continues to be refined through advanced pharmacokinetic studies. New data from animal models suggest that its therapeutic window may be wider than previously thought, especially when administered via controlled-release formulations or in combination with protective agents that mitigate cardiotoxicity. These developments are crucial for translating laboratory findings into clinical applications.

Looking forward, several clinical trials are currently investigating Ouabain Octahydrate derivatives for heart failure and cancer indications. The compound's unique mechanism of action and the growing understanding of its pleiotropic effects position it as a valuable tool for both basic research and therapeutic development in chemical biology and medicine.

• 88235-61-4(3β-[[6-O-(6-O-β-D-Glucopyranosyl-β-D-glucopyranosyl)-β-D-glucopyranosyl]oxy]-14-hydroxy-5α-card-20(22)-enolide)
• 129760-97-0(oleandrigenin beta-neritrioside)
• 53270-25-0(oleandrigenin beta-neritrioside)
• 56774-64-2(oleandrigenin beta-neritrioside)
• 129830-70-2(Odorobiosid-D)
• 1204704-33-5(10beta-hydroxy-19-nor-antiarigenin-3-O-beta-D-javopyranoside)
• 129830-71-3(Odorobiosid-D)
• 88660-21-3(3-[(6-deoxy-3-O-methylhexopyranosyl)oxy]-12,14,16-trihydroxycard-20(22)-enolide)
• 88673-30-7(3-{[2,6-dideoxy-4-O-(6-deoxyhexopyranosyl)hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide)
• 144300-16-3(Odorobiosid-D)